IgGenix

Solving allergies with precision antibody engineering

San Francisco Bay Area, United States · Founded 2019 · $75.0M raised

Employees
11–50
Founded
2019
Business Model
B2B
Total Funding
$75.0M
Last Round
$40.0M Series BFeb 2023
Rounds
3

About

IgGenix is a clinical-stage antibody discovery and development company using its proprietary SEQ SIFTER single-cell RNA-sequencing platform to identify and re-engineer rare human IgE antibodies into high-affinity IgG4 therapeutics. Its lead program, IGNX001, targets peanut allergy and has completed Phase 1 enrollment; the pipeline also includes food, environmental, and atopic disease programs.

Summary

IgGenix is a Biotech company based in San Francisco Bay Area, United States, founded in 2019. It has raised $75.0M in total across 3 rounds, most recently a $40.0M Series B round in Feb 2023. Investors include Khosla Ventures, Alexandria Venture Investments and Matthias Westman.

Tech & App Stack

3 technologies & apps tracked

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

Series BSeries BFeb 2023
$40.0M

Sign up to see all 3 rounds

Full funding history, per-round amounts, and investor participation.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

IgGenix on Indexed.vc
<a href="https://indexed.vc/companies/iggenix"><img src="https://indexed.vc/api/badge/company/iggenix" alt="IgGenix on Indexed.vc" width="260" height="76" /></a>